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To understand how the Bcl6 transcriptional
repressor functions in the immune system, we dis-
rupted its RD2 repression domain in mice.
Bcl6RD2MUTmice exhibit a complete loss of germinal
center (GC) formation but retain normal extrafollicu-
lar responses. Bcl6RD2MUT antigen-engaged B cells
migrate to the interfollicular zone and interact with
cognate T helper cells. However, these cells fail to
complete early GC-commitment differentiation and
coalesce as nascent GC aggregates. Bcl6 directly
binds and represses trafficking receptors S1pr1
and Gpr183 by recruiting Hdac2 through the RD2
domain. Deregulation of these genes impairs B cell
migration and may contribute to GC failure in
Bcl6RD2MUT mice. The development of functional
GC-TFH cells was partially impaired in Bcl6RD2
MUT
mice. In contrast to Bcl6/ mice, Bcl6RD2MUT ani-
mals experience no inflammatory disease or macro-
phage deregulation. These results reveal an essential
role for RD2 repression in early GC commitment and
striking biochemical specificity in Bcl6 control of
humoral and innate immune-cell phenotypes.
INTRODUCTION
In response to T cell-dependent (TD) antigen stimulation, anti-
gen-specific B cells migrate to the periphery of B cell follicles
and interfollicular zones of secondary lymphoid organs, where
they interact with cognate T helper cells within 1–3 days (Kerfoot
et al., 2011; Okada et al., 2005; Qi et al., 2008). After then, B cells
can follow one of three alternative fates by differentiating into ex-
trafollicular plasma cells, follicular germinal center (GC) B cells,
or recirculating early memory B cells (McHeyzer-Williams et al.,
2012). GC B cells undergo massive clonal expansion, somatic
hypermutation, and class switch recombination, after which
selected clones undergo differentiation into memory B cells
and long-lived plasma cells (Allen et al., 2007; Victora and Nus-
senzweig, 2012). T follicular helper (TFH) cells express the che-Cell Remokine receptor CXCR5 and costimulatory molecule PD-1 at
high levels and specialize in providing help to B cells during
the humoral immune response (Crotty, 2011). Antigen-present-
ing dendritic cells mediate the initiation of TFH cell differentiation
at early time points after immunization (Choi et al., 2011; Goenka
et al., 2011). Interactions with cognate B cells, especially GC B
cells within GCs, are critical for further polarization, mainte-
nance, and function of TFH cells at later stages of the immune
response (Choi et al., 2011; Kerfoot et al., 2011; Kitano et al.,
2011). Thus, the reciprocal development of GC B cells and TFH
cells is crucial for establishment of the GC reaction, including
the formation of high-affinity antibody and the generation of
long-lived plasma cells.
The Bcl6 transcriptional repressor is a master regulator of the
GC reaction required for development of both GCB cells and TFH
cells, respectively (Dent et al., 1997; Fukuda et al., 1997; John-
ston et al., 2009; Nurieva et al., 2009; Ye et al., 1997; Yu et al.,
2009). In addition, Bcl6 plays a key role in suppressing inflamma-
tory cytokine expression in macrophages (Toney et al., 2000).
Bcl6-deficient (Bcl6/) mice in addition to failing to form GCs
are sickly and die within weeks from a lethal inflammatory syn-
drome primarily driven by macrophages with secondary contri-
butions from Th2 and Th17 cells (Mondal et al., 2010; Toney
et al., 2000). However, from a mechanistic standpoint the func-
tion ofBcl6 is poorly understood outside of the context of already
established GC B cells. Bcl6 enables proliferation and tolerance
of DNA damage by silencing DNA damage sensing and cell cycle
checkpoint genes, and it also delays plasma cell differentiation
by repression of critical GC exit and plasma cell differentiation
genes (Bunting and Melnick, 2013; Klein and Dalla-Favera,
2008). However,Bcl6/mice display a complete loss of GC for-
mation with no evidence of the capacity to establish nascent GC
clusters (Dent et al., 1997; Fukuda et al., 1997; Ye et al., 1997),
suggesting that Bcl6 might have biological functions prior to
GC formation. Indeed, Bcl6 protein is upregulated in early
GC-committed B cells (i.e., ‘‘pre-GC B cells’’) outside GCs
3–5 days after immunization (Kerfoot et al., 2011; Kitano et al.,
2011) and plays an essential role in maintaining interactions
with TFH cell as well as subsequent migration and clustering
into GC structures, at least in part through repressing the expres-
sion of Gpr183, encoding the G protein-coupled receptor Ebi2
(Kitano et al., 2011; Shaffer et al., 2000).ports 8, 1497–1508, September 11, 2014 ª2014 The Authors 1497
Bcl6 functions as a transcription repressor via its N-terminal
BTB domain and middle ‘‘second repression,’’ or ‘‘RD2’’ domain
(Chang et al., 1996; Seyfert et al., 1996). A loss of function of the
BCL6 BTB domain markedly impairs survival and proliferation of
mature GC B cells in a B cell intrinsic manner, with no effects on
T cells or macrophages (Huang et al., 2013). Notably, unlike
Bcl6/ B cells, BTB-deficient B cells still form GCs although
their numbers and sizes are markedly reduced. This discrepancy
illustrates our incomplete understanding of the molecular under-
pinnings of Bcl6-mediated GC B cell development and suggests
that other functions of Bcl6 are dominantly involved in modu-
lating early pre-GC B cell fate.
In this study we generated mice in which the native Bcl6 locus
was engineered to produce a form of Bcl6 containing a mutant
RD2 domain that disrupts its repressor function. We found that
RD2 domain is essential for pre-GC B cell differentiation and
clustering into nascent GCwithin follicles, in part through repres-
sing key trafficking receptors S1pr1 and Gpr183 by recruiting
Hdac2. Thus, these findings implicate the Bcl6 RD2 domain as
defining the fate of activated B cells toward the GC phenotype,
which is mechanistically distinct from its role in enabling prolifer-
ation and survival upon induction of the proliferative burst within
GCs. The activities of Bcl6 can thus be parsed out into unique
biochemical elements, each contributing different actions to
the functionality of immune system.
RESULTS
Generation and Characterization of Bcl6 RD2 Mutant
Knockin Mice
Tomore precisely localize the repressor function of the Bcl6 RD2
domain, we first mapped theminimal region sufficient for its tran-
scription repression activity. The full-length RD2, which spans
the region from the BTB domain to the zinc finger domain (amino
acids 129 to 519), mediated strong transcriptional repression
similar to the Bcl6 BTB domain (Figures S1A and S1B). Progres-
sive truncation yielded a 45-amino acid region (amino acids 350
to 395) as the minimal domain containing a similar repressive ef-
fect as full-length RD2 (Figure S1B). This 45 amino acid domain
encompassed a known, functionally important KKYK motif
(amino acids 387 to 390). The introduction of K387Q, K388Q,
and K390Q substitutions (lysine at 387, 388, and 390 to gluta-
mine), mimics of acetylation of the KKYK, completely abrogated
transcriptional repression mediated by either the 45-amino acid
region or the full-length RD2 domain (Figure S1B).
It was reported that the Bcl6 middle region containing the RD2
domain binds to histone deacetylase 2 (HDAC2), MTA3-NuRD
complex, and CtBP (Bereshchenko et al., 2002; Fujita et al.,
2004; Mendez et al., 2008). We found that wild-type minimal
45-animo acid RD2 domain, but not its QQYQmutant form, inter-
acts with HDAC2 as well as NuRD subunits Mi-2 and MTA3, but
not CtBP, in coimmunoprecipitation assays (Figure S1C). Re-
porter assays showed that both HDAC2 and MTA3 contribute
to the repressor function of the minimal RD2 domain (Fig-
ure S1D). Collectively, these results show that a 45-amino acid
domain mediates the autonomous repressor function of the
Bcl6 RD2 domain and its activity can be disrupted through mu-
tations of key lysine residues.1498 Cell Reports 8, 1497–1508, September 11, 2014 ª2014 The AuWe next utilized a homologous recombination strategy to
introduce K387Q, K388Q, and K390Q point mutations into the
native Bcl6 locus in mice (Figures S1E and S1F). This enabled
us to generate a Bcl6 RD2 mutant knockin mouse strain (called
‘‘Bcl6RD2MUT’’ henceforth; Figure S1G). In contrast to Bcl6/
mice, Bcl6RD2MUT mice were born at the expected Mendelian
ratios and were grossly normal in growth and survival. Expres-
sion of themutant Bcl6 gene product was confirmed by immuno-
blotting and sequencing (Figures S1H and S1I). Quantitative
chromatin immunoprecipitation (QChIP) assays demonstrated
that endogenous Bcl6RD2MUT protein binds to target genes in
primary murine macrophages to a similar extent as WT Bcl6 pro-
tein and retains the ability to recruit SMRT corepressors through
the BTB domain (Figure S1J).
Bcl6RD2MUT Mice Display a Normal Extrafollicular
Responsebut aCompleteAbrogation of theGCReaction
Bcl6/ mice display a reduction of immature B cells in bone
marrow and mature B cells in spleen (Duy et al., 2010). However,
Bcl6RD2MUT display normal B cell development prior to the GC
stage (Figures S1K and S1L) and form normal splenic primary
lymphoid follicles (Figure S1M). Next, we studied the role of
the Bcl6 RD2 domain in the TD antigen immune response. TD an-
tigen stimulation first induces an extrafollicular response to give
rise to an early wave of low-affinity antibodies. We immunized
a cohort of age-matched WT and Bcl6RD2MUT mice with
sheep red blood cells (SRBCs), a T cell-dependent antigen.
Bcl6RD2MUT and WT mice produced a similar amount of splenic
NP-specific plasmablast or plasma cells (NP+CD138+B220lo-neg)
and splenic IgM and IgG NP-specific antibody secreting cells
at day 7 after immunization with 4-hydroxy-3-nitrophenylacetyl
conjugated to chicken gamma globulin (NP-CGG), a well-
defined TD antigen (Figures S2A and S2B).
At later time points, TD antigen immunization induces the GC
(follicular) response to produce high-affinity antibodies. Remark-
ably,Bcl6RD2MUT exhibited a complete absence of any GCs in B
cell follicles of spleens at day 5,10, and 14 after SRBC immuniza-
tion, revealed by immunochemistry (Figure 1A), similar toBcl6/
mice. A complete loss of GCs was also observed in Peyer’s
patches (Figure 1A). Accordingly, flow cytometry analysis
showed that CD38lo-negFas+ GC B cells were virtually undetect-
able in immunized Bcl6RD2MUT mice at day 10 after SRBC im-
munization (<0.1%; Figure 1B), identical to Bcl6/ mice. Both
CXCR5hiPD1hi GC-TFH and CXCR5
intPD1intTFH were profoundly
reduced in immunized Bcl6RD2MUT mice (0.7% ± 0.2% and
2.7% ± 0.4%, respectively; p < 0.01 versus WT; Figure 1C). As
expected, GC-TFH and TFH cells were virtually absent in immu-
nized Bcl6/ mice (<0.1 and <1.0, respectively; Figure 1C).
Similar defects were detected in Bcl6RD2MUT mice challenged
with NP-CGG (Figure S2C). Bcl6RD2MUT mice displayed pro-
gressively lower levels of total NP-specific immunoglobulins af-
ter day 7 after NP-CGG immunization, most strikingly at day 32
(Figure S2D). The titers of all high-affinity NP-specific immuno-
globulin isotypes, captured by NP4, were significantly lower in
Bcl6RD2MUT than WT mice at day 32 (p < 0.01; Figure S2E).
The ratio of titers of high-affinity IgG1 to those of total IgG1,
which indicates antibody maturation, was also lower in
Bcl6RD2MUT than WT mice (p < 0.01; Figure S2F). Collectively,thors
Figure 1. Complete Loss of GCs in
Bcl6RD2MUT Mice
(A–C) WT and Bcl6RD2MUT mice were immunized
i.p. with SRBCs.
(A) Representative immunohistochemical staining
for PNA, B220, and Bcl6 on paraffin-embedded
serial spleen sections and Peyer’s patches. Scale
bars, 200 mm. ND, not detected; n = 3 each time
point per group.
(B and C) Flow cytometry of murine splenic cells
10 days after immunization. The adjacent dot plots
indicate the percentage of Fas+ CD38lo-neg GC B
cells among total B cells (B), as well as
CXCR5hiPD1hi GC-TFH and CXCR5
intPD1int TFH
cells among total CD4+ T cells (C). N.S., not sig-
nificant; *p < 0.05 and **p < 0.01 (two-tailed t test).these data demonstrate that transcriptional repression through
the RD2 domain of Bcl6 is required for the GC response and
high-affinity immunoglobulin maturation, but dispensable for
the extrafollicular response.
The Bcl6 RD2 Domain Is Essential for GC B, but Not
GC-TFH, Cell Formation
The requirement of Bcl6 for GC formation is due to its dual and
cell autonomous role in the development of both GC B cells
and TFH cells. Moreover, the development of these two cell types
is interdependent. Thus, the loss of GC B cells and TFH cells
in Bcl6RD2MUT mice could be caused by B cell and/or T cell
deficiency. To determine the potential contribution of these cell
types to the Bcl6RD2MUT phenotype, we generated mixed
bone marrow chimeras by transferring 50% of congenic
CD45.1+ WT bone marrow cells together with 50% of CD45.2+
bone marrow cells from WT, Bcl6/, or Bcl6RD2MUT mice into
sublethally irradiated Rag1/mice, which were then immunized
after reconstitution (Figure 2A). As expected, CD45.2+ Bcl6/
donor cell-derived GC B cells, GC-TFH cells, and TFH cells
were essentially absent from CD45.1+ WT and CD45.2+Bcl6/
mixed chimeras (p < 0.01; Figures 2B and 2C). Analysis of
CD45.2+ Bcl6RD2MUT chimeras revealed a complete absence
of CD45.2+ GC B cells (Figure 2B), but yet still formed a normal
number of CD45.2+ TFH cells (p > 0.05) and approximately
60% CD45.2+ GC-TFH cells compared with WT donor T cells
(p < 0.05; Figure 2C), which was similar to a hypomorphic defect
observed in Bcl6+/ T cells (Yu et al., 2009). Together, these
results indicate that RD2-dependent repression is essentialCell Reports 8, 1497–1508, Sepfor the generation of GC B cells, but
were more dispensable for GC-TFH cell
differentiation.
RD2-Deficient B Cells Are Unable to
Support a Functional GC Reaction
We next examined whether the func-
tional defects in GC formation in
Bcl6RD2MUT mice were cell intrinsic to
GC B cells and/or GC-TFH cells. For
this we reconstructed chimeras by
transferring mMT bone marrow (80%)along with bone marrow cells (20%) from WT, Bcl6RD2MUT,
or Bcl6/ mice into sublethally irradiated Rag1/ recipients
(Figure 3A). The mMT bone marrow cells provide a source of
normal T cells, but not B cells, thus all B cells in these chi-
meras originate from tested donor bone marrow. GC B cells
were virtually absent in Bcl6RD2MUT mixed chimeras 10 days
after immunization with SRBCs (Figure 3B). Accordingly, titers
of total NP specific antibodies (binding NP26) were reduced
by 88% and the titers of high-affinity IgG1 NP-specific anti-
bodies (binding NP4) were reduced by 95% in Bcl6RD2MUT
versus WT mixed chimeras (p < 0.05 versus WT) 21 days after
NP-CGG immunization (Figure 3C). Notably, the impairment
in GC B cell numbers and titers of high-affinity antibodies
were indistinguishable between Bcl6RD2MUT and Bcl6/
mixed chimeras (Figure 3C), demonstrating that B cells abso-
lutely require the Bcl6 RD2 domain for GC formation and
functionality.
RD2-Deficient T Cells Are Modestly Impaired in
Supporting a Functional GC Reaction
The Bcl6 RD2 domain appears to play a relatively limited role in
instructing GC-TFH cell differentiation (Figure 2C). To determine
whether these cells were functionally impaired in driving hu-
moral immunity, chimeras were generated by transferring a
4:1 mixture of Tcrb/Tcrd/ and WT, Tcrb/Tcrd/ and
Bcl6RD2MUT, or Tcrb/Tcrd/ and Bcl6/ bone marrow
cells into sublethally irradiated Rag1/ recipients (Figure 3D).
In these chimeras the Tcrb/Tcrd/ strain contributes
normal B cells, whereas T cells are derived from tested WT,tember 11, 2014 ª2014 The Authors 1499
Figure 2. Intrinsic Defects in GC B, but Not TFH, Cells in Bcl6RD2
MUT Mice
(A) Schematic outline of generation of mixed chimeras and immunization.
(B and C) Flow cytometry and adjacent dot plots showing percent of Fas+ CD38lo-neg GC B cells among live B220+ cells (B) and percent of CXCR5hiPDhi GC-TFH
and CXCR5intPD1int TFH cells among live CD4
+ cells from CD45.1 or CD45.2 donors (C). The ratio was calculated by dividing percent GC B cells or TFH cells from
CD45.2 donor by that from CD45.1 donor. Each symbol represents an individual mouse, and small horizontal lines indicate means. Data are from three inde-
pendent experiments with four mice per genotype. N.S., not significant; *p < 0.05 and *p < 0.01 (two-tailed t test).Bcl6RD2MUT, or Bcl6/ marrow cells. Eight weeks after re-
constitution, animals were immunized with SRBCs or NP-
CGG. The frequency of GC B cells among splenic B cells in
Tcrb/Tcrd/ and WT mixed chimeras was 3.1% ± 0.3%
10 days after SRBC immunization, whereas GC B cells were
essentially undetectable in Bcl6/ mixed chimeras (<0.1%;
Figure 3E). Notably, Bcl6RD2MUT mixed chimeras displayed a
mild, albeit significant, reduction of GC B cells, with a frequency
of 1.8% ± 0.6% (p < 0.05 versus WT; Figure 3E). The titers of
total NP-specific IgG1 antibodies in NP-CGG immunized
Bcl6RD2MUT mixed chimeras were indistinguishable to WT (Fig-
ure 3F). In contrast, the titers of high-affinity NP-specific IgG1
antibodies in Bcl6RD2MUT chimers were significantly reduced
compared with WT chimeras (p < 0.05; one-tailed t test; Fig-
ure 3F). However, antibody titers were still significantly higher
in Bcl6RD2MUT mixed chimeras as compared with Bcl6/ chi-
meras (p < 0.05; Figure 3F). Taken together, these data indicate
that inactivation of the RD2 domain leads to a TFH functional
defect, which, although significant, is much less severe than
that caused by Bcl6 knockout.1500 Cell Reports 8, 1497–1508, September 11, 2014 ª2014 The AuTo gain some insight into the basis of this modest defect, we
isolatedCD45.2+ Bcl6RD2MUTGC-TFH andCD45.1
+WT counter-
parts from SRBC-immunized mixed CD45.1+ WT and CD45.2+
WT chimeras (Figure S3A) and examined the expression of
several keyTFHcell-associatedgenes including IL-21andBlimp1.
IL-21 is expressed by TFH cells and signals to B cells to regulate
GC responses (Linterman et al., 2010; Zotos et al., 2010). Blimp1
is an importantBcl6direct target andantagonistic regulator of TFH
cell differentiation (Johnston et al., 2009). Notably, Bcl6RD2MUT
GC-TFH expressed a lower abundance of Il-21 and higher levels
of Blimp1 compared with WT counterparts (Figure S3B). The
Bcl6 RD2 domain has been reported to repress Blimp1 transcrip-
tion in B cells (Fujita et al., 2004). We next analyzed whether RD2
deficiency might directly impair Bcl6-dependent repression of
Blimp1 transcription in T cells using a luciferase reporter driven
by the Blimp1b promoter, which contains the consensus Bcl6
binding site (Figure S3C) that is the major binding site for Bcl6 at
Blimp1 locus (Hatzi et al., 2013). Indeed, we observed that RD2
deficiency significantly impaired Bcl6-mediated repression of
the Blimp1b promoter in T cells (Figure S3D).thors
Figure 3. Severely Impaired Function of RD2-Deficient GC B Cells and Modest Defect in T Cells
(A) Schematic outline of generation of mMT chimeras and immunization.
(B) Flow cytometry of FAS+ CD38lo-neg GC B cells among live splenic B220+ cells from SRBC-immunized mMT chimeras.
(C) ELISA of NP-specific IgG1 in sera from NP26-CGG-immunized mMT chimeras.
(D) Schematic outline of generation of Tcrb/Tcrd/ chimeras and immunization.
(E) Flow cytometry of FAS+CD38lo-neg GC B cells among live splenic B220+ cells from SRBC-immunized Tcrb/Tcrd/ chimeras.
(F) ELISA of NP-specific IgG1 in sera from NP-CGG-immunized Tcrb/Tcrd/ chimeras.
Each symbol represents an individual mouse, and small horizontal lines indicate means (B, C, E, and F). Data are from two independent experiments with four
mice per genotype. RU, relative units; N.S., not significant; *p < 0.05 and **p < 0.01 (two-tailed t test).The Early Phase of the Bcl6RD2MUT B Cell Response
Appears Normal
The striking and complete defect in GC formation observed in
Bcl6RD2MUT mice is similar to Bcl6/ mice and different
than the Bcl6 BTB mutant mouse strain, in which GCs are
still observed at late time points (day 10) (Huang et al., 2013),
suggesting that the functional defect of Bcl6RD2MUT B cells
occurs at an early time point of GC development (day 4)
before the onset of rapid population expansion of GC B cells
(Calado et al., 2012). Indeed, SRBC-immunized BTB mutant
mice formed robust early GC clusters in spleen and Peyer’s
patches at day 4, whereas in Bcl6RD2MUT mice the ability
to develop early GC clusters was completely abrogated
(Figure S4A).Cell ReWe next examined the early stages of Bcl6RD2MUT B cell
development in response to TD immunization. To this end,
Bcl6RD2MUT mice were bred with a GFP-expressing strain and
their offspring further crossed to MD4 mice, which bear a trans-
genic B cell receptor that specifically binds the hen egg lyso-
some (HEL), to finally obtain GFP-Bcl6RD2MUT-MD4 mice. Red
fluorescent protein (RFP) mice were crossed to the WT MD4
background to generate RFP-MD4 mice. Naive B cells from
GFP-Bcl6RD2MUT-MD4 and RFP-WT-MD4 mice (at a 1:1 ratio)
were transferred together with cyan fluorescent protein (CFP) ex-
pressing ovalbumin (OVA)-specific T cells to recipients, which
were then immunized at the footpad with HEL-conjugated oval-
bumin (HEL-OVA) in complete Freund’s adjuvant (CFA) 2 days
later (summarized in Figure 4A). This protocol ensured theports 8, 1497–1508, September 11, 2014 ª2014 The Authors 1501
Figure 4. Bcl6RD2MUT B Cells Exhibit Normal Contacts with Cognate T Helper Cells but Fail to Cluster into Nascent GCs
(A) Schematic outline of experimental approach.
(B) Time lapse images of CFP-OT-II T cells interacting with WT RFP-MD4 B cells and GFP-Bcl6RD2MUT-MD4 B cells showing the tracks of motile T and B cells in
conjugate pairs (see also Movies S1 and S2). Time is shown in minutes:seconds.
(C) Distribution of T-B cell contact durations of a representative experiment described in the Experimental Procedures.
(D) Bcl6 staining in sections of draining popliteal lymph nodes 5 days after immunization. Nascent GC is identified as the Bcl6hi cell cluster (blue or white) and is
highlighted by the open circle. A representative region close to the GC is boxed and shown in the bottom panel. Open and filled arrows indicate Bcl6hi WT B cells
and Bcl6RD2MUT B cells, respectively. Scale bars, 50 mm.specific recruitment of MD4 B cells to the GC formation pathway
at the expense of the recipient B cell pool. SMARTA T cell recep-
tor (TCR) transgenic mice were used as recipients to eliminate
the endogenous T cell response to OVA. One day after immuni-
zation, time-resolved intravital imaging of adoptively transferred
fluorescent cells within popliteal lymph nodes (LNs) was per-
formed. LikeWTB cells,Bcl6RD2MUT B cells relocated to the pe-
riphery of B cell follicles and interfollicular zones (Figure 4B;
Movies S1 and S2). Moreover, analysis of T-B cell contact times1502 Cell Reports 8, 1497–1508, September 11, 2014 ª2014 The Auin vivo indicated that the duration of such interactions by
Bcl6RD2MUT B cells are comparable to that observed among
WT B cells, typically lasting longer than 30 min and often for
the duration of the imaging time period (Figures 4B and 4C;
Movies S1 and S2).
Bcl6RD2MUT B Cells Failed to Form Nascent GC Clusters
After immunization and initial cognate contact with T helper cells,
some antigen-specific B cells proceed toward pre-GC B cellthors
Figure 5. The BCL6 RD2 Domain Recruits
HDAC2 to Repress S1PR1 and GPR183
(A) Relative transcript abundance of S1PR1,
S1PR2, and GPR183 in human tonsillar GC B cells
(GCB) compared with naive B cells (NB) after
normalization of HPRT.
(B) ChIP-seq tags (y axis) are shown as a histogram
for the enrichment of BCL6, H3K4me2, and
H3K27ac in GC B cells and naive B cells for S1PR1
and GPR183 loci.
(C) Enrichment of indicated proteins at S1PR1 and
GPR183 loci in human tonsillar GC B cells.
(D–F) OCI-LY1 cells stably expressing a control
vector, siRNA-resistant BCL6 or BCL6RD2MUT
were transfected with BCL6 siRNA#1 for 2 days.
Relative transcript abundance of indicated genes
(D) and fold change of enrichment of indicated
proteins or histone marks at the S1PR1 locus (E)
were calculated compared with vector. Data are
representative of three independent experiments.
*p < 0.05 and **p < 0.01 (two-tailed t test). (F) GSEA
of the gene-expression profiles of BCL6 and
BCL6RD2MUT-expressing OCI-LY1 cells for
BCL6_repressed and GC_B_cell_upregulated
gene sets. FDR, false discovery rate (q value); NES,
normalized enrichment score. The cartoon illus-
trates that that RD2 mutant BCL6 is deficient in
repressing many BCL6 target genes and deficient
in enabling the GC B cell transcriptional program
as compared with WT BCL6.differentiation, characterized by upregulation of Bcl6 protein in
the outer follicle, and finally coalesce and form small GC clusters
in the follicle center 4–5 days after immunization (Kerfoot et al.,
2011; Kitano et al., 2011). We next examined the ability of trans-
ferred antigen-specific Bcl6RD2MUT B cells to form Bcl6hi pre-
GC B cells and GC structures in SMARTA TCR transgenic
mice at day 5 after immunization (Figure 4A). As expected, WT
RFP-MD4 B cells formed PNA+ GC clusters within follicles
on day 5 after immunization (Figure S4B). WT Bcl6hi RFP-MD4
B cells were predominantly found within GC and also in the
region around GC (Figure 4D). In contrast, Bcl6hi GFP-
Bcl6RD2MUT-MD4 B cells failed to self-aggregate or join GC
structures, although they remained Ki67+, and instead appeared
randomly distributed (Figure 4D; Figure S4C). Similar to WT B
cells, Ki67+ Bcl6RD2MUT-B cells were also observed within the
medullary cords and the periphery of follicles (data not shown),
including the area adjacent to the subcapsular sinus, previously
shown to support the extrafollicular formation of plasmablasts
(Kerfoot et al., 2011).
The Bcl6 RD2 Domain Specifically Controls Genes
Involved in B Cell Trafficking
The formation of GCs requires coordinated differential expres-
sion of specific lymphocyte trafficking factors. In murine B cells,
downregulation of Gpr183 (also known as Ebi2) is important for
the clustering of pre-GC B cells within follicle centers (Gatto
et al., 2009; Pereira et al., 2009). Upregulation of S1pr2 confines
GC B cells within GCs (Green et al., 2011). S1pr1 enables B cell
trafficking (Cinamon et al., 2004), and low S1pr1 levels in GC BCell Recells were suggested to enable their retention within follicles
(Green et al., 2011). Differential expression of these factors be-
tween murine GC and follicular B cells has been reported (Green
et al., 2011).We also observed a similar expression pattern in hu-
man GC and follicular B cells (Figure 5A). Thus, we asked
whether the BCL6 RD2 domain controls expression of these
factors.
Analysis of chromatin immunoprecipitation sequencing (ChIP-
seq) data (Be´guelin et al., 2013; Huang et al., 2013) showed that
BCL6 binds to distal regulatory sites associated with the
GPR183 and S1PR1 genes, respectively (Figure 5B). Both these
binding sites carry classical enhancer marks: histone 3 lysine 27
acetylation (H3K27ac) and histone 3 lysine 4 dimethylation
(H3K4me2) in naive B cells. In contrast, the active enhancer
mark H3K27ac (Creyghton et al., 2010) was clearly reduced in
the presence of BCL6 in GC B cells (Figure 5B), consistent
with the reduced abundance of GPR183 and S1PR1 mRNA.
QChIP assays for BCL6 repression complexes at the S1PR1
and GPR183 loci in primary human GC B cells showed that
HDAC2 was specifically bound along with BCL6 at both the
S1PR1 and GPR183 enhancer regions (Figure 5C). In contrast,
the core NuRD component Mi-2 and CtBP were absent from
these sites, although they still occupied their known binding sites
with BCL6 at intron 3 of PRDM1 for Mi-2 and with the BCL6 pro-
moter for CtBP (Figure S5A).
Next, we performed functional assays in GC-derived lym-
phoma cells to study the transcriptional mechanism of the
BCL6 RD2 domain. BCL6 knockdown in BCL6-dependent
OCI-Ly1 lymphoma cells derepressed both GPR183 andports 8, 1497–1508, September 11, 2014 ª2014 The Authors 1503
S1PR1 (p < 0.05; Figure S5B) and resulted in upregulation of
S1PR2 (possibly an indirect effect since BCL6 is not known to
activate genes). Ectopic expression of WT, but not RD2 mutant
BCL6, recruited HDAC2 to the S1PR1 locus in BCL6 null MutuIII
cells (Figure S5C). BCL6 knockdown in OCI-LY1 cells impaired
recruitment of HDAC2 to S1PR1 andGPR183 loci, with a conse-
quent increase of H3K27 acetylation of both loci. (Figure S5D)
HDAC2 knockdown also induced H3K27 acetylation at both of
these loci in these cells (Figure S5D).
To confirm whether repression of S1PR1 and GPR183 is spe-
cifically dependent on the BCL6 RD2, we performed rescue ex-
periments in which we introducedWT or RD2mutant BCL6 using
expression constructs insensitive to siRNA into OCI-LY1 cells in
which endogenous BCL6 was depleted by small interfering RNA
(siRNA) knockdown (Figure S5E). RD2 mutant BCL6 failed to
repress S1PR1 and GPR183 expression (Figure 5D). Moreover,
RD2 mutant BCL6 was unable to recruit HDAC2 and deacety-
late H3K27 at the S1PR1 locus as compared with WT BCL6
(Figure 5E). Similar results were observed in an additional GC-
derived lymphoma cell line (Figure S5F). Finally, migration as-
says in GC-derived lymphoma cells revealed that S1PR1 inhibits
S1PR2-induced migration in the presence or absence of chemo-
tactic cytokine CXCL12 (Figure S5G), consistent with antago-
nistic functions of S1PR1 and S1PR2 in B cell trafficking. Overall,
the data suggest that BCL6 RD2 domain-dependent recruitment
of HDAC2 mediates silencing of S1PR1 and GPR183 and indi-
rectly induces upregulation of S1PR2, contributing to the clus-
tering of B cells within follicles.
The BCL6 RD2 Domain Regulates Gene Sets Linked to
the GC Phenotype
To examine whether the BCL6 RD2 domain might regulate addi-
tional genes linked to the GC phenotype, we performed RNA
sequencing to compare the gene expression profiles of endog-
enous BCL6-depleted OCI-LY1 cells rescued with either WT
or RD2 mutant BCL6. Unsupervised hierarchical clustering
showed that the WT BCL6 and RD2 mutant gene expression
profiles were clearly distinct and distributed to distinct clusters
(Figure S5H). Gene set enrichment analysis (GSEA) revealed
that a canonical set of genes, known to be downregulated by
BCL6 in B cell lymphoma cells (Shaffer et al., 2000), was signif-
icantly repressed in WT BCL6 versus RD2 mutant BCL6
(normalized enrichment score [NES] = 1.50, false discovery
rate [FDR] = 0.02; Figure 5F). Conversely, a canonical GC B
cell gene set, consisting of genes that are upregulated in GC
B cells compared with other B cell types (Shaffer et al., 2001),
was significantly enriched (NES = 2.17, FDR = 0.00) in WT
BCL6 as compared with RD2 mutant BCL6 expressing B cells
(Figure 5F). This result is consistent with the notion that the
RD2 domain functions of BCL6 are required for B cells to ac-
quire the GC phenotype.
The RD2 Domain Is Dispensable for the Anti-
inflammatory Function of Bcl6
Bcl6/ mice are born at sub-Mendelian frequency. The pups
exhibit developmental delays and runted size (Dent et al.,
1997; Fukuda et al., 1997; Ye et al., 1997). Within weeks they
develop a fatal inflammatory syndrome driven by macrophage1504 Cell Reports 8, 1497–1508, September 11, 2014 ª2014 The Auand Th2 cells (Mondal et al., 2010; Toney et al., 2000). In marked
contrast,Bcl6RD2MUTmicewere born at the expected ratios, ex-
hibited normal body weights (Figure 6A), and lived normal
healthy lifespans. Bcl6RD2MUT animals did not exhibit any evi-
dence of tissue damage or cellular infiltrates upon histopatholo-
gy exam of various target organs of the Bcl6/ inflammatory
disease including lungs (Figure 6B) and other organs (data not
shown). Bcl6 represses expression of inflammatory chemokines
such as Ccl2, Ccl3, Ccl6, Ccl7, and Il-1a in macrophages. The
loss of Bcl6 results in marked upregulation of these genes in
macrophages and splenic B cells, which is believed to contribute
to the lethal Bcl6/ phenotype (Shaffer et al., 2000; Toney et al.,
2000). These inflammatory response genes were only minimally
increased in resting or lipopolysaccharide (LPS)-stimulated
macrophages from Bcl6RD2MUT mice as compared with their
WT counterparts (Figure 6C). Moreover, the abundance of these
inflammatory cytokines in Bcl6RD2MUT was comparable toWT B
cells in either the resting or LPS-stimulated status (Shaffer et al.,
2000) (Figure 6D). Finally, Bcl6/mice display a high proportion
of Th2 and Th17 cells, which play a critical role in the manifesta-
tion of inflammatory disease (Mondal et al., 2010; Toney et al.,
2000). This phenotype can be further induced and aggravated
by immunization. However, Bcl6RD2MUT mice displayed similar
numbers of Th2 (1.6% ± 0.2% versus 2.0% ± 0.3%) and Th17
cells (0.5% ± 0.1% versus 0.6% ± 0.2%) to WTmice after immu-
nization (Figure 6E), further demonstrating that Bcl6 RD2 domain
functions are dispensable to the actions of BCL6 in repressing
the inflammatory phenotype.
DISCUSSION
The development of GCs is a sequential and complex process,
during which BCL6 serves as master regulator in multiple cell
types (Goodnow et al., 2010; Klein and Dalla-Favera, 2008;
McHeyzer-Williams et al., 2012), There are many unanswered
questions regarding the mechanisms and stages at which Bcl6
controls this process. Dissection of these events is further
complicated by the diverse functions of Bcl6 in B cells, T cells,
etc., as well as the multifaceted biochemical mechanisms of ac-
tion of Bcl6 (Bunting and Melnick, 2013).
After T cell-dependent antigen stimulation, Bcl6 protein begins
to accumulate in pre-GCB cells in the outer follicle regions and is
maintained at high levels within GC B cells (Kerfoot et al., 2011;
Kitano et al., 2011). Its role in mature, established GCs is fairly
well defined and is linked to its silencing of cell cycle, DNA dam-
age sensing, and apoptosis checkpoint genes as well as repres-
sion of genes involved in terminal differentiation (Bunting and
Melnick, 2013; Klein and Dalla-Favera, 2008). These well-known
GC B cell functions are mediated through Bcl6 BTB domain-
dependent recruitment of the SMRT, NCOR, and BCOR core-
pressors (Hatzi et al., 2013; Huang et al., 2013; Polo et al.,
2004). In contrast, the significance of Bcl6 in B cells at the pre-
GC stage has not been confirmed, and the molecular basis for
Bcl6-mediated pre-GC B cell differentiation remains unknown.
Our current data showing that the Bcl6 RD2 domain plays an
essential role in pre-GC B cell differentiation and nascent GC
formation thus significantly extends knowledge of how B cells
adopt the GC fate under the control of a specific BCL6thors
Figure 6. Bcl6RD2MUT Mice Fail to Develop Macrophage and/or TH2 Driven Inflammatory Disease
(A) Body weight of indicated mice at 8 weeks of age (n = 6).
(B) Representative hematoxylin and eosin-stained lung sections from indicated mice. Scale bars, 200 mm.
(C and D) mRNA expression of indicated genes in resting or LPS-treated bone marrow-derived macrophages (C) and splenic B cells (D) from indicated mice
(n = 3). Datawere obtained from three independent experiments and are represented as fold-upregulation relative toWT resting cells after normalizationwithHprt.
Numbers adjacent to the error bars indicate fold induction.
(E) Percentage of IFNY, IL-4, and IL-17 secreting cells among CD4+ cells from indicated mice. The data shown indicate mean + SD from three mice. N.S., not
significant; *p < 0.05, **p < 0.01, and ***p < 0.001 (two-tailed t test).biochemical mechanism distinct from its known canonical
function (Figure 4). The profound defect in early pre-GC differen-
tiation in RD2-deficent B cells best explains the complete abro-
gation of GC formation in Bcl6 knockout mice and emphasizes
the importance of Bcl6 in early GC B cell commitment.
The canonical BCL6 repressive mechanism of action in GC B
cells is mediated by recruitment of the SMRT, NCOR, and BCOR
corepressors to the BCL6 BTB domain (Hatzi and Melnick,
2014). However, we find that Bcl6 BTB mutant mice are still
mostly capable of forming early GC clusters. This phenotype is
in contrast to the complete abrogation of GC formation observed
in BCL6RD2mutantmice. Hence, whereby BCL6mediates early
steps in commitment to the GC fate and clustering into nascent
GCs through the RD2 domain, once GCs are established, Bcl6 is
then required tomaintain the proliferation and survival by repres-Cell Resing genes through its BTB domain. These findings suggest a
model of sequential and biochemically distinct biological func-
tions of BCL6 at different GC B cell developmental stages (Fig-
ure S6). It is also possible that the RD2 domain might also
contribute to later events in established GCs such as regulation
of terminal differentiation (Fujita et al., 2004; Parekh et al., 2007),
although such functions cannot be assessed in the RD2 animal
model developed here.
This pre-GC B cell differentiation deficiency caused by RD2
loss of function was explained at least in part by the finding
that the BCL6 RD2 domain is required to repress expression of
the key migration factors GRP183 and S1PR1. Downregulation
of GRP183 is critically important for B cell migration into the fol-
licle center (Gatto et al., 2009; Pereira et al., 2009). S1PR1 plays a
key role in enabling B cell trafficking out of follicles (Cinamonports 8, 1497–1508, September 11, 2014 ª2014 The Authors 1505
et al., 2004). Our finding that BCL6 directly represses these
genes in GC cells suggests a role for BCL6 at an early stage of
the GC response, whereby BCL6 can enable ‘‘capture’’ of B cells
within follicles to enable their clustering. At the same time,
S1PR2 upregulation in GC B cells confines them to an S1P-low
niche within follicles (Green et al., 2011). We observed that
S1PR1 overexpression promoted GC-type B cell migration and
antagonized S1PR2 (Figure S5G). Taken together, the data sug-
gest that dynamic regulation and equilibrium of S1PR1 and
S1PR2 is a critical event in the early pre-GC phase of the humoral
immune response, controlled at least in part through BCL6 direct
binding and repression of S1PR1.
From a mechanistic standpoint, the BCL6 RD2 domain re-
presses the GPR183 and S1PR1 loci by recruiting HDAC2,
but not MTA3-NuRD, to suppress the enhancer activation
mark H3K27ac at their distal regulatory elements. However,
these data do not exclude the possibility that other as yet un-
known corepressor proteins may bind with BCL6-HDAC2
repression complexes to these key target genes. Taken
together with recent findings showing that BCL6 BTB domain
corepressors distribute to different sets of genomic loci with
unique functions in GC B cells (Hatzi et al., 2013), these data
suggest that transcriptional programming by BCL6 is exqui-
sitely compartmentalized through linkage of distinct biochem-
ical functions to genes involved in specific immunological and
biological functions.
In contrast to Bcl6/ T cells, Bcl6RD2MUT T cells were
partially impaired in their ability to form GC-TFH cells (Figure S6),
which is somewhat similar to a hypomorphic defect observed in
Bcl6+/ T cells (Yu et al., 2009). This defect is partially explained
by the fact that RD2 mutant GC-TFH cells exhibited reduced IL-
21 expression and increased Blimp1. Repression of Blimp1 by
BCL6 is known to critical for GC-TFH cell differentiation and func-
tion (Johnston et al., 2009). IL-21 is expressed by GC-TFH cell to
promote GC B cell development and maintenance (Linterman
et al., 2010; Zotos et al., 2010). Unlike Bcl6/ mice, inflamma-
tory responses andmacrophage regulationwere not significantly
disrupted in Bcl6RD2MUT mice. Neither loss of the BTB domain
lateral groove nor the RD2 domain are sufficient to elicit deregu-
lation of inflammatory signaling, which must instead be more
reliant on other functions of Bcl6. The dominant mechanism
may be linked at least in part to the previously reported compe-
tition with STAT proteins for binding to promoters of genes regu-
lating inflammatory signaling (Dent et al., 1997; Huang et al.,
2013) (Figure S6).
In conclusion, we identify the repressor function of the Bcl6
RD2 as a critical molecular mechanism required for early stages
of GC B cell differentiation. Through recruitment of HDAC2 and
perhaps additional cofactors, the RD2 domain mediates repres-
sion of genes that must be downregulated for BCL6 to commit to
GC formation and form clusters within lymphoid follicles.EXPERIMENTAL PROCEDURES
Animals
Mice were housed in the specific pathogen-free animal facility at theWeill Cor-
nell Medical College and experiments performed using protocols approved by
Institutional Animal Care and Use Committee. Generation of the Bcl6RD2MUT1506 Cell Reports 8, 1497–1508, September 11, 2014 ª2014 The Auknockin mouse and other animal are described in the Supplemental
Information.
Bone Marrow Chimera Studies
Eight-week-old sublethally irradiated Rag1/ mice were used as recipients.
To generate mixed chimera (Figure 2A), 4 3 106 bone marrow cells from a
mixture of WT CD45.1 and CD45.2 (WT, Bcl6/, or Bcl6RD2MUT) with a ratio
of 1:1 were injected intravenously into recipients. To generate mMT chimera
(Figure 3A), 43 106 bonemarrow cells from amixture of mMT andWT,Bcl6/,
or Bcl6RD2MUT mice with a ratio of 4:1 were intravenously transferred into
recipients. For generation of Tcr/ chimeras (Figure 3D), recipients received
a mixture of 80% bone marrow cells of Tcrb/Tcrd/ donors and 20%
WT, Bcl6/, or Bcl6RD2MUT. Eight weeks after reconstruction, the recipients
were immunized intraperitoneally (i.p.) with SRBCs (Cocalico Biologicals) for
10 days for analysis of GC formation, or the recipients were immunized i.p.
with NP26-CGG (Biosearch Technologies) in Alum (Thermo Sciences) at
21 days for evaluation of antibody production.
Cell Isolation, Adoptive Transfers, and Immunizations
MD4-specific B cells were isolated from the spleens and lymph nodes of mice
by immnomagnetic purification with the negative selection EasySep Mouse B
Cell Enrichment Kit (StemCell Technologies). T cells were purified from the
spleens and lymph nodes of OT-II mice with the negative selection EasySep
CD4+ T Cell Enrichment Kit (StemCell Technologies). For both intravital imag-
ing and histology experiments (Figure 4), 2.5 3 106 GFP-Bcl6RD2MUT-MD4 B
cells, 2.5 3 106 RFP-WT-MD4+ B cells, and 1.53 106 T cells were transferred
for all time points. Cells were injected intravenously into SMARTA recipients
that were immunized with 75 mg of HEl-OVA emulsified in CFA (Thermo Sci-
ences) at 1.5 mg/ml in the right hind footpad.
Intravital Microscopy
The popliteal lymph nodes of anesthetized mice were imaged 1 day after im-
munization. Mice were initially anesthetized with an i.p. injection of a ketamine
and xylazine mixture and were subsequently kept anesthetized with a nebu-
lized isoflurane-O2 gas mixture. Animals were immobilized on a custom-built
stage, and the right popliteal lymph node was surgically prepared as previ-
ously described (Mempel et al., 2004). For imaging acquisition, an Olympus
BX61WI fluorescence microscope with a 203, 0.95 NA water immersion
Olympus objective and dedicated single-beam LaVision TriM laser-scanning
microscope (LaVision BioTec) was controlled by Inspector Pro software.
The microscope was outfitted with a Chameleon Vision II Ti:Sapphire laser
(Coherent) with pulse precompensation. Emission wavelengths of 390–
480 nm (blue, CFP), 500–550 nm (green, GFP), and 565–665 nm (red, RFP)
were collected with an array of three photomultiplier tubes (Hamamatsu).
For 4D analysis of cell migration, stacks of 24 optical sections with 3 mm z-
spacing were acquired every 30 s for 60–120 min with the laser tuned to a
wavelength of 880 nm. Each xy plane spanned 400–500 mm in each dimension
with a resolution of 0.977 mm per pixel.
Statistical Analysis
Student’s t test was performed for statistical analysis. The software GraphPad
Prism 5was used for this analysis. A p valuemore than 0.05 is considered to be
no significance.
Additional methods are provided in the Supplemental Experimental
Procedures.
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